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The current classiﬁcation of lymphoid neoplasms is based on clinical information, morphology, immunophenotype, and
molecular genetic characteristics. Despite technical and scientiﬁc progress, some aggressive B-cell lymphomas with features
overlapping between two diﬀerent types of lymphomas remain diﬃcult to classify. The updated 2008 World Health Organization
(WHO) classiﬁcation of Tumours of the Hematopoietic and Lymphoid Tissues has addressed this problem by creation of two new
provisional categories of B-cell lymphomas, unclassiﬁable; one with features intermediate between diﬀuse large B-cell lymphoma
and classical Hodgkin lymphoma and the second with features intermediate between diﬀuse large B-cell lymphoma and Burkitt
lymphoma. We review here the diagnostic criteria of these two provisional entities and discuss new scientiﬁc ﬁndings in light of
the 2008 WHO classiﬁcation.
1.Introduction
The current classiﬁcation of lymphoid neoplasms is based
on clinical information morphology, immunophenotype,
and molecular genetic characteristics. Most lymphomas
can be accurately classiﬁed. However, some lymphomas
present with features transitional between diﬀuse large B-
cell lymphomas (DLBCLs) and classical Hodgkin lymphoma
(cHL) or DLBCL and Burkitt lymphoma (BL), and these
are diﬃcult to classify [1]. These lymphomas have been
reported in the literature using diﬀerent terms, such as
borderline lymphomas, B-cell lymphomas unclassiﬁable,
atypical Burkitt lymphoma, Burkitt-like lymphomas, or
gray zone lymphomas. The term “Gray Zone Lymphoma”
was ﬁrstly used in 1998 at the “Workshop on Hodgkin’s
disease and related diseases” to designate lymphomas at the
border of cHL and other entities [2]. This term was then
further extended to lymphomas with overlapping features
between BL and DLBCL. The 2008 updated WHO classi-
ﬁcation of Tumours of the Hematopoietic and Lymphoid
Tissues proposed to assign these gray zone lymphomas to
provisional categories called B-cell lymphomas unclassiﬁ-
able with features intermediate between DLBCL and cHL
(BCLu-DLBCL/cHL) and B-cell lymphomas unclassiﬁable
with features intermediate between DLBCL and BL (BCLu-
DLBCL/BL) [3]. The reason to create these provisional
categories is to enable to collect for further studies and to
maintain the “purity” of well-deﬁned categories. This would
be particularly relevant for conducting clinical studies. This
paper focuses on these two provisional entities introduced in
the 2008 WHO classiﬁcation of Tumours of the Hematopoi-
etic and Lymphoid Tissues.
2. B-Cell Lymphoma, Unclassiﬁable, with
FeaturesIntermediatebetweenDiffuse Large
B-Cell Lymphoma and ClassicalHodgkin
Lymphoma (BCLu-DLBCL/cHL)
Primary mediastinal diﬀuse large B-cell lymphoma
(PMBCL) and classical Hodgkin lymphoma of nodular
sclerosingsubtype(cHL-NS)haveclinical,histopathological,2 Advances in Hematology
and molecular similarities (Table 1). Both lymphomas
present as an anterior mediastinal mass with involvement of
the thymus and/or supraclavicular lymph nodes and aﬀect
preferentially young women. Median age of presentation
is slightly older in PMBCL (35 years) than in cHL-NS (30
years) [4]. The histopathological features of PMBCL include
ad i ﬀuse proliferation of large cells with clear abundant
cytoplasm and ﬁne compartmentalizing sclerosis. Reed-
Sternberg-like cells may be present [5, 6], and distinction
from cHL-NS can sometimes be diﬃcult. The neoplastic
cells in PMBCL express B-cell markers (CD20, CD79a,
CD19, PAX5) and lack expression of HLA class I antigens
and surface immunoglobulin (Ig). However, expression of
Ig-associated transcription factors BOB1, OCT2, and PU1
is preserved in contrast to cHL [7, 8]. CD30 is expressed in
70% of cases and tumour cells are typically CD23 positive.
Seventy per cent of PMBCL and 10% of cHL express the
MAL protein linking them histogenetically to the thymic
asteroid medullary B cells [9, 10]. EBV is absent in PMBCL.
On gene expression proﬁling studies, the PMBCL gene
signature diﬀers from that of germinal centre B-cell-like
and activated B-cell-like DLBCL. Highly expressed genes
include MAL, I n t e r l e u k i n e4i n d u c e dg e n e1( I L 4 I 1 ), TARC,
NFkB2, and PDL1/L2 [11, 12]. Interestingly, the PMBCL
g e n es i g n a t u r ea p p e a r e dt ob em o r er e l a t e dt oc H Lg e n e
signature as both represent downregulation BCR pathway
signalling, constitutive NF-kappa B activation, activation
of the cytokine-JAK-STAT pathway, high expression of
extracellular matrix elements, overexpression of the TNF
family members, and aberrant activation of the P13K/AKT
pathway [11–17]. Recent studies have highlighted many
genetic similarities as well. Both entities show gains at 2p15
(RELlocus)and9p24(JAK2 locus)andbreaksatCIITA(38%
of PMBCL and 15% of cHL) [18–20]. The presence of CIITA
rearrangement signiﬁcantly correlates with shorter disease-
speciﬁc survival for patients with PMBCL [20]. Altogether,
these features point to a similar histogenesis.
In recent years, cases with morphological and immu-
nophenotypic features transitional between PMBCL and
the nodular sclerosis subtype of cHL have been reported.
These cases, which were initially referred to as “gray zone
lymphomas,” were assigned in the 2008 WHO classiﬁcation
to a provisional category designated B-cell lymphoma,
unclassiﬁable, with features intermediate between DLBCL
andcHL(BCLu-DLBCL/cHL).Theselymphomaswithinter-
mediate features have been reported mostly from Western
countries, and they seem to be less frequent in sub-Saharan
Africa and Asia [3].BCLu-DLBCL/cHLusuallypresentswith
mediastinal manifestations, but also include occasional cases
involving nonmediastinal lymph node sites. Involvement of
lung(bydirectextension),liver,spleen,andbonemarroware
documented. In contrast to PMBCL, nonlymphoid organs
are rarely inﬁltrated [3]. Interestingly, these lymphomas
are probably more frequent in young men and have a
more aggressive clinical course and poorer outcome than
either cHL or PMBCL [21, 22]. From the morphological
point of view BCLu-DLBCL/cHL shows typically sheet-like,
conﬂuent growth of pleomorphic tumour cells embedded
in a diﬀusely ﬁbrotic stroma. The majority of tumour cells
classically resemble lacunar cells and Hodgkin cells. How-
ever, the tumour shows marked variation of morphological
aspects ranging from cHL to DLBCL/PMBCL in the same
tumour. There is usually a sparse inﬂammatory inﬁltrate
present with only scattered eosinophils, lymphocytes, and
histiocytes. Typically necrotic areas do not include neu-
trophilic inﬁltrates. Immunohistochemically, B-cell program
is usually preserved in the tumour cells with expression
of the transcription factors PAX5, OCT-2, and BOB.1, but
this proﬁle is accompanied by expression of typical “cHL
markers” like CD15 and CD30. Surface Ig expression is
absent. MAL, a typical marker for PMBCL [10], is expressed
in at least a proportion of cases [3]. Diagnostic criteria
include, for example, cases morphologically resembling
PMBCL but with strong expression of CD15, absence of
CD20 or presence of EBV [3] .C a s e sr i c hi nt u m o u rc e l l s
resemblingcHL,whicharestronglypositiveforCD20and/or
other B-cell markers, are also included in this category [23].
The existence of composite (cHL and PMBCL at the
time of diagnosis) or sequential/metachronous lymphomas
(cHL following a diagnosis of PMBCL or vice versa) suggests
that some lymphomas in the mediastinum show lineage
plasticity with a shift over time toward the one or the
other entity [21] which may be due to epigenetic and not
genetic mechanisms. Based on this consumption Eberle
et al. studied the DNA methylation status which is the best
established epigenetic marker so far from 10 mediastinal
gray zone lymphomas (MGZLs) compared to 10 cHL-NS,
10 PMBCL, and 10 nodal DLBCL cases [24]. MGZL cases
had epigenetic proﬁles intermediate to cHL and PMBCL
but clearly distinct from DLBCL. PMBCL and cHL-NS
presented with distinct methylation signatures. cHL-NS
showed presence of de novo hypermethylation and absence
of de novo hypomethylation within CpG islands and in a
fraction of promoters outside CpG islands. These results are
in line with other studies suggesting that the development of
Reed-Sternberg cells may be due to gene silencing by DNA
methylation [25, 26]. In contrast, PMBCL showed both de
novo hypermethylation and hypomethylation. Interestingly,
HOXA5 hypomethylation was exclusively found in MGZL,
and the biological relevance of this ﬁnding remains to be
explored.
Eberle and colleagues studied the genetic features
of 27 MGZL and 6 mediastinal composite or synchro-
nous/metachronous lymphomas by ﬂuorescence in situ
hybridization. They demonstrated ampliﬁcation in 2p16.1
(REL/BCL11A locus) and alterations in 9p24.1 (JAK2/PD2
locus) in 33% and 55% of the patients, respectively. In
addition, rearrangement of the CIITA locus at 16p13.13 and
gains of 8p24 (MYC) were both observed in 27% of the cases
each [27]. These very recent ﬁndings underline the plasticity
of mediastinal BCLu-DLBCL/cHL not only on morphologic
and immunophenotypic but also on molecular grounds.
Identiﬁcation of BCLu-DLBCL/cHL will hopefully
enable to better characterize them and above all to develop
an optimal therapeutic approach. The clinical management
of these patients is actually a challenge for clinicians as cHL
and PMBCL require diﬀerent therapies. Due to the rarity
of the disease and the complexity of diagnostic criteria, theAdvances in Hematology 3
Table 1: Common and distinguishing features of PMBCL, cHL-Nodular sclerosis (NS), and B-cell lymphoma, unclassiﬁable, with features
intermediate between DLBCL and cHL (BCLu-DLBCL/cHL). Modiﬁed after Hasserjian et al. [23].
PMBCL cHL-NS BCLu-DLBCL/cHL
Common features
Age Young patients Young patients Young patients
Gender Female predominance Female predominance Male predominance






lymph nodes or more
rarely other lymph nodes
Morphology Compartmentalizing ﬁbrosis Fibrosis in thick bands
Conﬂuent, sheet like
growth of pleomorphic
tumor cells with diﬀuse
ﬁbrotic stroma Variability
from area to area
Therapy response Radiotherapy sensitive Radiotherapy sensitive
Immunophenotype
Lack of Ig-Expression
Lack of HLA I expression
Frequent CD30 expression
Expression of MAL and CD23
Lack of Ig-expression
Lack of HLA I expression
CD30 expression
Transitional features






REL (2p15) and JAK2 gains (9p24)
CIITA breaks
Activation: NF-kappaB, JAK-STAT
(incl. STAT6), and P13K/AKT pathway
High expression of extracellular
matrix elements, overexpression of
TNF family members
Expression of HLA-I
REL (2p15) and JAK2 gains (9p24)
CIITA breaks
Activation: NF-kappaB, JAK-STAT
(incl. STAT6), and P13K/AKT pathway
High expression of extracellular
matrix elements, overexpression of
TNF family members





Clear cells often homogenous (but
Reed Sternberg cells may occur)
Little or no inﬂammatory background
Hodgkin cells and Reed Sternberg cells
Typical inﬂammatory background
Immunophenotype
B-cell markers preserved (CD20,
CD79a, PAX5) B-cell transcription
factors present (BOB.1 and OCT-2)
CD15 absent
Absence of EBV
B-cell markers lacking or only weakly
or heterogeneously expressed
(especially PAX5) B-cell transcription
factors usually negative
CD15 may be present
EBV may be present
optimal therapy for these patients remains unclear. In a
small series of patients with mediastinal BCLu-DLBCL/cHL,
Traverse-Glehen et al. suggested that patients might beneﬁt
better from therapy designed for aggressive B-cell non-
Hodgkin lymphoma than those applied to patients with cHL
[21]. However, these results need validation on a larger series
of patients.
3. B-Cell Lymphoma, Unclassiﬁable, with
FeaturesIntermediatebetweenDiffuseLarge
B-Cell Lymphoma and Burkitt Lymphoma
(BCLu-DLBCL/BL)
In order to understand the concept of this new category
of lymphoma, we will brieﬂy review the diagnostic criteria
for Burkitt lymphoma (BL) according to the updated WHO
classiﬁcation of lymphoid neoplasms.
BL includes three epidemiologic variants, the endemic
(so-called African type with 100% EBV association), the
sporadic,andtheimmunodeﬁciency-associated(mostlyHIV
infected patients). Additionally, cases presenting with a
leukemic picture (formerly known as L3 ALL) and with-
out signiﬁcant lymphadenopathy are also included. The
atypical/Burkitt-like and the plasmacytoid variants are no
longer mentioned [23].
The diagnostic criteria for BL are quite strict. Mor-
phologically, the tumour cells are medium sized, with
monotonous cytology presenting with round nuclei with
ﬁnely clumped and dispersed chromatin and multiple
basophilic paracentrally situated nucleoli. The cytoplasm
is deeply basophilic and usually contains lipid vacuoles
(which may better be seen in imprints). The growth pattern
is diﬀuse, and the tumour cells often seem to grow in
a cohesive way. The proliferation fraction is extremely
high (>90%) with many mitotic ﬁgures accompanied by4 Advances in Hematology
Table 2: Common and distinguishing features of BL, DLBCL, and B-cell lymphoma, unclassiﬁable, with features intermediate between
DLBCL and BL (BCLu-DLBCL/BL).
BL DLBCL BCLu-DLBCL/BL
Common features
Age Young children and less
frequent young adults
Less frequent in children but
frequent in adults of all age
groups
Mainly diagnosed in adults
Gender Male predominance No real predominance
Localization Often extranodal (jaw and
iliac region) Nodal and extranodal
Often extranodal (no predominant
region) often widespread disease
leukemic presentation is possible
Morphology
Frequent mitotic ﬁgures and
apoptosis often with starry sky
pattern
Frequent mitotic ﬁgures and
apoptosis may be present
Frequent mitotic ﬁgures and apoptosis
often with starry sky pattern
resembling BL
Immunophenotype CD10, BCL-6 positive, BCL-2
negative
“BL immunophenotype” (CD10,
BCL-6 positive, BCL-2 negative)
may be present






Typical IG-MYC fusion may be
present









Small nucleoli at the
p e r i p h e r y ,m i t o t i cr a t ea l w a y s
very high (Ki67 > 90%)
Pleomorphic large blastic tumor
cells, often inﬂammatory
inﬁltrate, mitotic rate variable
Genetical and
molecular features
Typical cMYC fusion with IG
light or heavy chain locus,
simple karyotype
More complex karyotypes
possible (sign of progression)
Other types of cMYC fusions can
be present (other than IG as a
partner), complex karyotype
possible
Combination of BCL2 and/or BCL6
breaks possible (so-called “double or
triple hit lymphomas”)
a high fraction of apoptosis and often a starry sky pat-
tern due to the background occurrence of tingible body
macrophages [3]. In contrast with previous classiﬁcation,
increased nuclear irregularity, slight nuclear pleomorphism,
and/or more prominent, single nucleoli are allowed if the
immunophenotypeandthemolecularcharacteristicsﬁtwith
the diagnosis of BL. These lymphomas previously classiﬁed
as “Burkitt-like” or “atypical Burkitt” lymphoma are now
included in the “Burkitt lymphoma” category, and hence
the terms “Burkitt-like” or “atypical Burkitt” lymphoma
should not be used any longer. This approach is supported
by molecular studies, which have revealed that the cases
classiﬁed morphologically as “atypical” BL have a molecular
signature similar to classical BL [23, 28].
The immunohistophenotype required for the diagnosis
of BL is strong CD10 and BCL6 positivity, negativity for
BCL2, and a Ki67 index of near 100% (at least 90%) [3].
Weak positivity for BCL2 is accepted, but strong expression
for BCL2 and a proliferation fraction below 90% are strong
contraindications for a diagnosis of BL [23].
On genetics, most cases show rearrangement of MYC
at 8q24 to the IG heavy chain (14q32) or less frequent
to the kappa (22q11) or lambda (2p12) light chain loci.
The breakpoints are diﬀerent in endemic and sporadic BL.
Endemic BLs present with breakpoints occurring within the
VJregionoftheIGH locus,whilesporadicBLmainlypresent
with breakpoints occurring within IGH switch regions of
the IGH locus, which may point to the diﬀering maturation
status of the two types [29, 30]. Importantly, up to 10% of
BL may lack a MYC gene translocation by FISH. To date it
is not clear if this is due to a failure of detection or if such
lymphomasreallyexist.However,MYC-negativeBLinadults
is characterised by downregulation of microRNA hsa-mir-
34b and recurrent duplications of chromosome 11 [28, 31,
32].However, these MYC-negativeBLshave tobe completely
typical on morphological and immunophenotypic grounds
to be classiﬁed as BL although this opinion is not shared by
all authors [1].
However, in view of the strict diagnostic criteria, there
remain cases, which are not completely typical, either
on morphological and/or immunohistochemical/genetic
grounds and therefore are diﬃcult to assign to either BL
or DLBCL category (classical common and distinguishing
featuresbetweenthesetwoentitiesarelistedinTable 2).Gene
expression proﬁling (GEP) studies reveal that though the
GEPsignatureofBLandDLBCLaredistinct,inaproportionAdvances in Hematology 5
of B-cell lymphomas the GEP signature is intermediate
between BL and DLBCL [28]. Such cases were diagnosed
either as BL or DLBCL on morphologic and immunohis-
tochemical grounds by expert hematopathologists, and pos-
sibly inappropriate therapy was rendered for some patients.
Based on these observations, the recent WHO classiﬁcation
created a provisional entity, B-cell lymphoma, unclassiﬁable,
with features intermediate between DLBCL and BL (BCLu-
DLBCL/BL). The reasons for the creation of this new entity
are mostly similar to those of BCLu-DLBCL/cHL. Firstly,
it intends to collect cases with intermediate features under
the same name, and secondly it segregates “clean” BL and
DLBCL, which is extremely helpful for clinical trials. On the
other hand, it also creates diﬃculties to clinicians, as the
therapeutic strategies diﬀer greatly in adults between BL and
DLBCL, and there has been no consensus, on how to treat
patients with BCLu-DLBCL/BL.
BCLu-DLBCL/BL are relatively rare and mainly diag-
nosed in adults [3] .T h e yr e p r e s e n tu pt o5 %o fa d u l t
aggressive B-cell lymphomas and usually occur in extranodal
sites sometimes associated with leukemic involvement [33].
By deﬁnition, BCLu-DLBCL/BL harbour intermediate mor-
phological and immunohistochemical features between BL
and DLBCL [3]. They may be medium or large cells, usually
withahighproliferationfractionandstarryskypattern,with
an atypical immunophenotype (lack of CD10 and/or strong
BCL2 expression) that precludes the diagnosis of BL. Most
of them are of germinal centre subtype with expression of
CD10, BCL6 and lack of MUM1 [33].
Cytogenetic characterization of these BCLu has shown
that a proportion of them harbours a complex karyotype
with two main genetic events—usually cMYC alterations
together with BCL2 and/or BCL6, less commonly CCND1
rearrangements, designated the so-called “double hit” lym-
phomas (DHL). Some patients may have a previous history
of low-grade lymphoma such as follicular lymphoma, CLL,
or mantle cell lymphoma, and the acquisition of cMYC
alteration may represent a secondary genetic event [33].
Importantly, lymphomas with a typical DLBCL mor-
phology that have a MYC breakpoint are excluded from
the category of BCLu-DLBCL/BL. Up to 15% of DLBCL
have MYC translocations [23, 34], and they are generally
associated with an inferior outcome [35, 36].
The clinical evolution of patients with double-hit lym-
phomas is dramatic with a median survival of 4.5 months,
and they are usually resistant to either conventional CHOP-
like regimens or to intensive therapy used to treat BL.
However, factors associated with a better survival have been
identiﬁed, which include non-IGH MYC partner, BCL2
protein expression, and rituximab inclusive chemotherapy
[37].
Altogether, this category of lymphoma appears hetero-
geneous and remains diﬃcult to diagnose in day-to-day
practice based on morphological and immunohistochemical
grounds. Interphase FISH with BCL2, BCL6, and cMYC
DNA probes provides a useful diagnostic tool to identify
these DHL. Adult cases in which BL or DLBCL/BL is a
diagnostic consideration should be tested for MYC, BCL2,
and BCL6 rearrangements, and if MYC break is associated
with BCL2 and/or BCL6 rearrangements, the case should
be classiﬁed as DLBCL/BL irrespective of other features
[23].
A very recent paper from the group of Reiner Siebert
[38] reviewed the “grey zone” between BL and DLBCL
from a genetic perspective. This paper aims to clarify the
diﬀerent deﬁnitions of intermediate lymphomas and to
propose a subclassiﬁcation based on genetic aberrations. The
“intermediate lymphoma” group from GEP studies and the
BCLu-DLBCL/BL from the WHO classiﬁcation are by far
not identical. The intermediate group of GEP is deﬁned
of a group of lymphomas not meeting the proﬁling of
either molecular BL or for molecular DLBCL. Therefore,
this category represents a wastebasket for all lymphomas,
which do not ﬁt into the two molecularly deﬁned entities.
On the other hand, the BCLu-DLBCL/BL entity deﬁned
by the WHO contains all lymphomas, which does not
meet the criteria of either BL or DLBCL on morphologic,
immunohistochemical, and classical genetic grounds and
represents a heterogeneous group of diseases. However, the
following aggressive B-cell lymphomas are excluded from
BCLu-DLBCL/BL: cases with typical DLBCL morphology
with a very high proliferation index, typical DLBCL with
a MYC translocation, and typical BL in which a MYC
rearrangement cannot be demonstrated and those with IG-
MYC rearrangement as the only abnormality, since they
probably correspond to real BL with atypical morphology.
Salaverria and Siebert [38] proposed a simple approach
based predominantly on age and genetic aberrations to
classify these aggressive B-cell lymphomas into biologically
meaningful and clinically recognizable subgroups.
In children, the classiﬁcation into BCLu-DLBCL/BL has
currently no inﬂuence on therapy or outcome and either
intermediate lymphomas according to both GEP and WHO
classiﬁcation are infrequent in patients under the age of 18
years [3, 39] and do not seem to have an adverse prognosis.
Almost all childhood “intermediate lymphoma” present
with IG-MYC fusion, and BCL2 breaks are almost always
absent. Therefore, it seems that in children “intermediate
lymphomas” represent rather true biologic BL, which were
classiﬁed as “intermediate” in the GEP due to secondary
aberrations [38]. In contrast some morphological DLBCLs
in children show a GEP signature of molecular BL with
more than half of them being IG-MYC positive, suggesting
that the presence of the MYC fusion is mostly responsible
for its given molecular signature. Since the MYC fusion is
very likely to be the ﬁrst event in lymphoma development,
complexkaryotypesareindicatorsofdiseaseprogressionand
inferior outcome and do not indicate an IG-MYC fusion as a
secondary event in children.
In adult patients the situation is rather diﬀerent and the
subclassiﬁcation of aggressive B-cell lymphomas has a true
impact on treatment decisions and prognosis. Salaverria and
Siebert [38] suggest that adult aggressive B-cell lymphomas
lacking typical BL morphology and phenotype can be
classiﬁed thereafter into four diﬀerent genetic subcategories
according to their MYC status as follows.
(1) IG-MYC-Positive Mature Aggressive Lymphomas with
Simple Karyotype Lacking Typical BL Morphology and/or6 Advances in Hematology
Phenotype. These cases represent a spectrum ranging from
cases that would be classiﬁed as BL to up to DLBCL based on
the WHO classiﬁcation, since the WHO considers morphol-
ogy, immunophenotype, and genetic characteristics as being




(2) IG-MYC-Positive Mature Aggressive B-Cell Lym-
phomas with Complex Karyotype, Lacking Typical BL Mor-
phology,and/orPhenotypeCarryingaHighGeneticComplexy.
These cases can correspond to BL with progression or
DLBCL with secondary MYC break. However, like in the ﬁrst
group it is not easy to set a cutoﬀ between complex and
simple karyotype, since there a standard reference method
is not deﬁned.
(3) Non-IG-MYC-Positive Mature Aggressive B-Cell Lym-
phomas. MYC translocations can involve partners other than
the IG heavy or light chain loci. Those translocations are
almost exclusively considered as secondary events. These
translocations are exceedingly rare in BL but represent up
to half of MYC translocations in BCLu-DLBCL/BL [3, 28].
Those cases are probably cases with a diﬀerent primary
genetic event (BCL2, BCL6 break, or others) and acquire
the MYC-break secondarily and may develop very complex
karyotypes.
(4) Double Hit-Positive Mature Aggressive B-Cell Lym-
phomas. These lymphomas carry either IG-MYC fusion
or non-IG-MYC fusion in combination with either BCL2
and/or BCL6 breaks. By deﬁnition these lymphomas would
also conform to the previously deﬁned group. But this
speciﬁc group comprises of >30% of MYC-translocation-
positive lymphomas in elderly patients and has an aggressive
clinical course. However, Salaverria and Siebert [38] pointed
out that further studies are needed to clarify: if double hit
lymphomas are diﬀerent from other MYC-positive non-BL
cases and if the diﬀerent types of combinations (DLBCL/BL
or DLBCL with BCL2 and/or BCL6 break and IG-MYC or
non-IG-MYC fusion) inﬂuence the outcome and behavior of
these lymphomas.
In addition, there are also MYC-translocation-negative
aggressive B-cell lymphomas with features intermediate
between BL and DLBCL. Here the “intermediate” status
is deﬁned according to the WHO criteria by histology
and immunophenotype. This group probably represents a
heterogeneous group of mainly DLBCL, but little is known
about this category to date. Salaverria and Siebert [38]
suggest that this genetic classiﬁcation should be tested for
reproducibility and clinical impact in future clinical trials.
In conclusion, since the publication of the 2008 WHO
classiﬁcation, several groups have tried to better characterize
these two new provisional entities of B-cell lymphomas,
unclassiﬁable with intermediate features. Eberle and col-
leagues [24, 27] have shed new insights on the epigenetic
and cytogenetic characteristics of BCLu-DLBCL/cHL which
highlight the plasticity of the tumour cells and the molec-
ular continuum between PMBCL and cHL. Regarding the
second category of B-cell lymphoma, BCLu-DLBCL/BL, the
situation is more complex. This category appears extremely
heterogeneous and remains diﬃcult to diagnose in day-
to-day practice based on morphological and immunohis-
tochemical features. The genetic approach proposed by
Salaverria is interesting and supports the fact that the detec-
tionofchromosomalabnormalitiesinthediagnosticworkup
of aggressive B-cell lymphomas is becoming increasingly
important.
Further studies are needed to better deﬁne the diagnostic
criteria of BCLu-DLBCL/BL and allow clinicians to conduct
clinical trials to deﬁne the optimal therapy which remains
unclear to date.
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